Herbert Irving Comprehensive Cancer Center
Investigator
Mark Stein, MD
Phone
212-305-5874
Email
mns2146@cumc.columbia.edu

Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in the field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute.

Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer.


Clinical Studies Managed By This Investigator:
Condition Study Title
Solid Tumors [ CLOSED ] Study of Safety of New Investigational Study Drug Alone and with Nivolumab in Advanced Solid Tumors
Solid Tumors [ CLOSED ] Study of LY3321367 Alone or in Combination with LY3300054 in Patients with Solid Tumors
Kidney Cancer [ CLOSED ] Study of Antibody Drug in Patients with Advanced Renal Cell Carcinoma
Cancer [ CLOSED ] Study of Drug (XmAb20717) in Subjects with Advanced Solid Tumors (DUET-2) - Melanoma, Breast Cancer, Lung Cancer, Stomach Cancer
Bladder Cancer [ CLOSED ] A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)
Solid Tumors [ CLOSED ] NKTR-214 in Combination with Pembrolizumab or Atezolizumab in Patients with Advanced or Metastatic Cancer (NSCLC, Bladder, or Melanoma)
Cancer [ CLOSED ] Study of Vaccine (GEN-009) in Adult Patient with Melanoma, NSCLC, Head and Neck Cancer, Bladder Cancer, or Kidney Cancer
Prostate Cancer IRONMAN: International Registry for Men with Advanced Prostate Cancer
Prostate Cancer [ CLOSED ] Study of HPN424 in Patients With Advanced Prostate Cancer
Prostate Cancer [ CLOSED ] Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Prostate Cancer Study of androgen deprivation therapy followed by chemoimmunotherpy for newly metastatic hormone-sensitive prostate cancer (mHSPC)
Solid Tumors Feasibility, Safety, and Activity Study of BPX-601 in Subjects With Previously Treated Advanced Solid Tumors
Prostate Cancer Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
Solid Tumors A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Solid Tumors [ CLOSED ] Study of XmAb22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
Cancer Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Prostate Cancer [ CLOSED ] A Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Prostate Cancer
Kidney Cancer [ CLOSED ] Cabozantinib With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Kidney Cancer (COSMIC-313)
Cancer [ CLOSED ] Study of RTX-240 in Adults with Relapsed/Refractory or Locally Advanced Solid Tumors
Kidney Cancer Cyto-KIK Trial: CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Prostate Cancer Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Prostate Cancer [ CLOSED ] PLX2853 with Abiraterone Acetate, Prednisone, and Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cancer Study of BAY 1895344 in Combination with Chemotherapy for Patients with Advanced Cancer
Cancer [ CLOSED ] Study of GEN-011 for Adult Patients with Advanced Cancer
Cancer [ CLOSED ] First-in-Human Study of DS-7300a in Subjects with Advanced Cancer
Prostate Cancer Study of ADXS-504 in Patients with Prostate Cancer
Cancer Study of INCB106385 Alone or in Combination with INCMGA00012 in Patients with Advanced Cancer
Prostate Cancer Study of JNJ-75229414 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Prostate Cancer Study of XmAb20717 Alone or in Combination with Chemotherapy in Patients with Prostate Cancer
Prostate Cancer Study of Cabozantinib in Patients with Prostate Cancer who Previously Received Anti-Androgen Therapy
Prostate Cancer Study of JNJ-78278343 in Patients with Advanced Prostate Cancer